Acrivon Therapeutics (NASDAQ:ACRV) Given “Overweight” Rating at Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research report released on Wednesday morning,Benzinga reports. Several other research firms have also commented on ACRV. KeyCorp began coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. HC […]
Cantor Fitzgerald restated their overweight rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research report released on Wednesday morning,Benzinga reports. Several other research firms have also commented on ACRV. KeyCorp began coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. HC […]
